{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-029848","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.197343+00:00","generated_at":"2026-06-14T00:55:32.074465+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ocuphire Pharma enters separation agreement with former CEO Sooch; $1.18M in lump sums","bullets":["$678,756 lump sum (base salary + pro rata bonus) plus $500,000 second lump sum after 6 months.","Stock options vest through April 19, 2024; exercisable until later of original expiration or April 19, 2026.","Restricted stock units vest as if employed through April 19, 2024.","Health insurance premiums paid for 12 months post-separation, subject to no other coverage.","Agreement includes non-competition, non-solicitation, mutual release and non-disparagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-029848","json":"https://secwatch.observer/filing/0001140361-23-029848.json","markdown":"https://secwatch.observer/filing/0001140361-23-029848.md","text":"https://secwatch.observer/filing/0001140361-23-029848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123029848/0001140361-23-029848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123029848/brhc20054327_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:55:32.074465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8eca985e23","claim":"Sooch departed as Chief Executive Officer at Opus Genetics, Inc..","evidence_excerpt":"Pursuant to the Separation and Release Agreement, Ms. Sooch will receive certain benefits in connection with Ms. Sooch being terminated without cause on April 19, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123029848/0001140361-23-029848-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}